ACROBIOSYSTEMS (301080.SZ): files for listing on HKEX: No.1 China Protein

NewTimeSpace News: On 30 September 2026, ACROBIOSYSTEMS CO., LTD (301080.SZ) filed an application with the Hong Kong Stock Exchange for a Main Board listing, with China Merchants Securities International acting as sole sponsor. According to the prospectus, the Company is principally engaged in the research, development, production and sale of recombinant proteins, antibodies and analytical detection kits, and its product portfolio integrates biological reagents and a suite of technical services, enabling it to provide customised solutions that address key needs of biopharmaceutical R&D from early target discovery to clinical trials.

The prospectus stated that, vertically, the Company's product portfolio covers a toolchain spanning target discovery, drug screening and optimisation through to preclinical research, ensuring experimental continuity and consistent, comparable data; horizontally, it deeply integrates reagent products such as recombinant proteins with its technical capabilities to address key industry R&D bottlenecks such as the expression of difficult-to-express proteins; and through the synergy of products and data across preclinical and clinical trial stages, it achieves full traceability of research results and maintains consistency of datasets. As of the latest practicable date, the Company offers over 5,000 SKUs of products and various technical services, all manufactured or provided in accordance with applicable internationally and industry-recognised quality standards and frameworks, including ISO 9001:2015, ISO 13485:2016, current Good Manufacturing Practice, the Medical Device Single Audit Program (MDSAP) and Rx-360.

According to Frost & Sullivan, based on 2025 revenue, the Company ranked first among all Chinese suppliers and third among all suppliers in the global recombinant protein market, with a global market share of 2.7%, and ranked third among all suppliers in China's biological reagents industry with a market share of 2.6%. The Company also disclosed that from 2023 to 2025, it achieved a higher revenue growth rate than the top five players in the global biological reagents market by revenue.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.